Review Article
The Biphasic Role of Microglia in Alzheimer’s Disease

Tetsuya Mizuno

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

Correspondence should be addressed to Tetsuya Mizuno, tmizuno@riem.nagoya-u.ac.jp

Received 28 December 2011; Accepted 29 February 2012

Academic Editor: Akio Suzumura

Copyright © 2012 Tetsuya Mizuno. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neuroinflammation is involved in the pathogenesis of Alzheimer’s disease (AD). Microglia, macrophage-like resident immune cells in the brain, play critical roles in the inflammatory aspects of AD. Microglia may be activated by oligomeric and fibrillar species of amyloid β (Aβ) that are constituents of senile plaques and by molecules derived from degenerated neurons, such as purines and chemokines, which enhance their migration and phagocytosis. The main neurotoxic molecules produced by activated microglia may be reactive oxygen species, glutamate, and inflammatory cytokines such as tumor-necrosis-factor-α and interleukin-1β. These molecules differentially induce neurotoxicity. Aβ itself directly damages neurons. In terms of neuroprotective properties, microglia treated with fractalkine or IL-34 attenuate Aβ neurotoxicity by Aβ clearance and the production of antioxidants. Therefore, regulation of the microglial role in neuroprotection may be a useful therapeutic strategy for AD.

1. Introduction

Microglia, macrophage-like immune cells in the central nervous system (CNS), cluster around the senile plaques that along with polymorphous amyloid β (Aβ) deposits are the pathological hallmarks of Alzheimer’s disease (AD). Microglia have a biphasic neurotoxic-neuroprotective role in the pathogenesis of AD. In regard to their neurotoxic properties, microglia may be involved in the inflammatory component of AD [1, 2]. In AD, the trigger molecule for microglial activation may be Aβ and molecules derived from degenerated neurons may enhance microglial neurotoxicity [3]. Aβ exists in different assembly forms including monomers, oligomers, and fibrils. Both oligomeric Aβ (oAβ) and fibrillar Aβ (fAβ) have been shown to stimulate microglial secretion of proinflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor-necrosis-factor-α (TNF-α); chemokines including monocyte chemotactic-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1); complement components; free radicals such as reactive oxygen species (ROS), including superoxide anions and hydroxy radicals [4, 5]. Glutamate also plays an important role in microglial neurotoxicity in AD. Activated microglia produce large amounts of glutamate, which induces excitotoxicity via N-methyl-D-aspartate (NMDA) receptor signaling [6–9]. Chronic activation of extrasynaptic NMDA receptors leads to increased Aβ production [10]. Aβ itself is toxic to neurons in AD, with oAβ being more toxic than fAβ (Figure 1). The toxicity of oAβ manifests itself in terms of synaptic dysfunction, including inhibition of hippocampal long-term potentiation, facilitation of long-term depression, and disruption of synaptic plasticity [11, 12]. It is therefore necessary to evaluate microglial neurotoxicity apart from Aβ neurotoxicity.

In regard to its neuroprotective properties, microglia attenuate Aβ neurotoxicity by Aβ clearance, including phagocytosis and degradation of Aβ and the production of antioxidants and neurotrophic factors [13–15]. In the present paper, we focus on the trigger molecules that mediate microglial activation and the mechanisms of microglial neurotoxicity mediated by ROS glutamate, and inflammatory cytokines. We also discuss the neuroprotective role of microglia in AD.

2. The Trigger Molecules That Mediate Microglial Activation

2.1. Fibrillar Aβ. Aβ, the key mediator of AD, is processed from the amyloid precursor protein (APP). The most common isoforms are Aβ1-40 and Aβ1-42, which are the
major constituents of senile plaques. \(A\beta_1-42\) is more prone to aggregate than \(A\beta_1-40\). Initial \(A\beta\) deposition begins with \(A\beta_1-42\), but not with \(A\beta_1-40\). In the process of \(A\beta_1-42\) aggregation, many types of soluble \(oA\beta\) are formed: dimers, trimers, tetramers, dodecamers, \(A\beta\)-derived diffusible ligands, and annular protofibrils [16–18]. Stimulation of microglia with \(fA\beta\) reportedly results in the Syk kinase- and NF\(\kappa\)B-dependent production of TNF-\(\alpha\), iNOS, and peroxynitrite [19]. However, the ability of \(fA\beta\) to activate microglia is generally low or absent when \(fA\beta\) is used as the sole stimulant. Recent reports have clarified that \(fA\beta\) can activate microglia via Toll-like receptor 2 (TLR2) [20] or interaction with cell surface receptor complexes. TLR2, TLR4, and TLR6 have been shown to be essential components of the receptor complexes for microglial activation. The coreceptor CD14 and TLR2 and 4 complex is required for \(fA\beta\)-stimulated microglial activation [21]. The class B scavenger receptor CD36 and TLR4 and 6 complex is also involved in the activation of microglia by \(fA\beta\). The signals mediated by this receptor complex induce IL-1\(\beta\) production in microglia [22].

**2.2. Oligomeric \(A\beta\).** The patterns of microglial activation caused by \(fA\beta\) and \(oA\beta\) are different. In addition, studies of microglial activation with \(oA\beta\) have yielded controversial results. \(oA\beta\) activates microglia by increasing levels of phosphorylated Lyn, Syk kinase, and p38 MAP kinase, which results in the production of IL-6 and a decrease in MCP-1 [23]. On the other hand, \(oA\beta\) does not produce several proinflammatory mediators commonly induced by lipopolysaccharides (LPS), such as prostaglandin E2, glutamate, TNF-\(\alpha\), IL-1\(\beta\), and IL-6. There is a report that \(oA\beta\) at low nanomolar concentrations induces neurotoxicity by increasing the production of nitric oxide (NO) as well as the activity of scavenger receptor A and the Ca\(^{2+}\)-activated potassium channel KCa3.1 [24]. \(oA\beta\) induces neuronal ROS through a mechanism requiring NMDA receptor activation [25]. ROS is also induced by \(fA\beta\) and \(oA\beta\) in microglia [26]. In contrast to the above reports, our data showed that both \(fA\beta\) and \(oA\beta\) failed to induce toxic molecules such as TNF-\(\alpha\), NO, and glutamate in microglia and to enhance these molecules in LPS-activated microglia (Figure 2) [15]. The synthetic \(oA\beta\) that is used
Figure 2: Inflammatory molecules produced by Aβ- or LPS-activated microglia. In primary microglial culture, administration of 5 μM oAβ42 or 5 μM fAβ42 for 24 h does not induce the production of neurotoxic mediators such as TNF-α, glutamate, or nitrite, a stable breakdown product of NO. While microglia activated with 1 μg/mL LPS produce these molecules, both oAβ42 and fAβ42 do not enhance the production.

for in vitro studies contains oligomers of different sizes and shapes, and microglia may respond to this heterogeneous oAβ mixture in various ways. Moreover, synthetic oAβ preparations are less potent than oAβ isolated from the supernatant of transfected cell cultures.

2.3. The Molecules Derived from Degenerated Neurons. Recent findings have indicated that damaged neurons are not merely passive targets of microglia but rather regulate microglial activity through nucleotides and chemokines [27]. Damaged neurons release several substances that activate microglia, for instance purines, including ATP [28] and UDP [29]; chemokines, such as CCL-21 [30]; glutamate [31]. However, these molecules do not always induce microglial neurotoxicity. ATP regulates microglial branch dynamics and mediates a rapid microglial response toward injured neurons. UDP triggers microglial phagocytosis via P2Y6 receptors. The chemokine CCL-21, released by damaged neurons, activates microglia via the CXCR3 receptor. Excessive neuronal glutamate is released as a result of neurodegenerative processes. Microglial cells express the AMPA and kainate subtypes of ionotropic glutamate receptors [32]. Metabotropic glutamate (mGlu) receptor 2, mGlu3, and mGlu5 are expressed in microglia [33, 34]. Glutamate serves as an activation signal for microglia, and activation of mGluR2 on microglia promotes neurotoxicity. However, microglial mGluR5 provides neuronal protection by suppressing the NO and TNF-α production induced by blood protein fibri-nogen [34].

3. The Neurotoxic Molecules Produced by Microglia

3.1. ROS. Oxidative damage to protein, lipids, polysaccha-rides, and DNA is involved in the pathogenesis of AD [35]. The expression of NADPH oxidase, a multisubunit enzyme complex responsible for the production of ROS, is upregulated in AD [36]. Microglial NADPH oxidase is activated by fAβ [37, 38], and NADPH oxidase activation subsequently causes neurotoxicity through two mechanisms: (1) extracellular ROS produced by microglia are directly toxic to neurons, and (2) intracellular ROS function as a signaling mechanism in microglia to amplify the production of several proinflammatory and neurotoxic cytokines [39]. ROS are induced in the mitochondrial membranes of both neurons and microglia, causing subsequent oxidative damage in the early stages of disease progression. Loss of mitochondrial membrane potential and increase of ROS production have been demonstrated in studies of AD patients as well as in transgenic mice models of AD [40, 41]. An increase in hydrogen peroxide and a decrease in cytochrome oxidase activity were found in young Tg2576 mice prior to the appearance of Aβ plaques [40]. Oxidative stress has been shown to contribute to the onset of cognitive dysfunction caused by Aβ [42].

A recent report showed that fAβ and oAβ induced ROS in microglia through the TRPV1 cation channel, also known as the capsaïcin receptor, and that pretreatment with fAβ or oAβ induced microglial priming through Kv1.3 K(+) channels, that is, increased ROS production upon secondary stimulation with the phorbol ester PMA [26]. The translo-cation of chloride intracellular channel 1 from the cytosol to the plasma membrane is also involved in microglial ROS generation [43].

Neuronal ROS induced by Aβ can be selectively dysfunc-tional as well as degenerative. Overstimulation of excitatory NMDA receptors can lead to excessive ROS. Antioxidative enzyme heme oxygenase-1 (HO-1) is a microsomal enzyme that oxidatively cleaves heme to produce biliverdin, carbon monoxide, and iron [44]. Aβ binds to heme to promote a functional heme deficiency and induces mitochondrial dys-function and neurotoxicity [45]. APP also binds to HO, and oxidative neurotoxicity is markedly enhanced in cerebral...
3.2. Glutamate. Activated microglia release large amounts of glutamate through upregulation of glutaminase expression and induce excitotoxicity through NMDA receptor signaling [7, 47, 48]. Microglial glutamate production is reported to be induced by APP, but not Aβ [48]. Excessive glutamate increases Ca²⁺ influx via the NMDA receptor, resulting in Ca²⁺/calmodulin-dependent protein kinase (CaMK) activation. NO induced by CaMK inhibits mitochondrial function. Stimulation of synaptic NMDA receptors enhances prosurvival signals through the activation of cAMP response element-binding protein (CREB) and the extracellular signal-regulated kinase (ERK) cascade [49, 50], whereas calcium flux through extrasynaptic NMDA receptors overrides these functions, causing mitochondrial dysfunction and neuronal cell death [51, 52]. A recent report suggested that chronic activation of extrasynaptic NMDA receptors leads to sustained neuronal Aβ release via amyloidogenic APP expression [53].

Focal bead-like swelling in dendrites and axons, known as neuritic beading, is a neuropathological sign that is a feature of neuronal cell dysfunction preceding neuronal death in various diseases such as ischemia, epilepsy, brain tumor, and AD [54–57]. We found that glutamate from activated microglia induces neuritic beading by impairing dendritic and axonal transport through NMDA receptor signaling [7]. Moreover, we demonstrated that gap junction hemichannels are the main avenue of excessive glutamate release from neurotoxic activated microglia [6]. The blockade of gap junction hemichannels by glycyrrhetinic acid derivatives significantly prevents activated microglia-mediated neuronal death in vitro [7, 58, 59] and in vivo in rodent models of transient ischemic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, and AD [60–62]. In the APP/PS1 transgenic mouse model of AD, glycyrrhetinic acid derivatives improved memory impairments without altering Aβ deposition [62]. oAβ is directly neurotoxic as a result of inducing glutamate release from hippocampal neurons and may contribute to dysregulation of excitatory signaling in neurons [63].

3.3. Inflammatory Cytokines. oAβ, but not fAβ, has been shown to increase levels of TNF-α and IL-1β in rat microglial cultures [64]. However, gene expression analysis of microglia using cDNA arrays has confirmed that the upregulation of TNF-α and IL-1β is caused by both oAβ and fAβ [65]. TNF-α is a well-characterized proinflammatory cytokine involved in many neuroinflammatory cascades, including autocrine activation of microglia [66] and direct apoptosis via activation of extrinsic pathway-associated TNF receptors [67, 68]. TNF-α enhances microglial glutaminase expression, glutamate production, and cell-surface expression of gap junction hemichannels [6]. Synergistic and autocrine activities of TNF-α may cause the release of large amounts of glutamate, resulting in excitotoxic neuronal death [69]. TNF-α has been shown to directly upregulate the expression of the AMPA receptor GluR1 subunit in mouse hippocampus and cerebral cortex neurons [70] and to exacerbate AMPA-induced neuronal death at high doses [71]. TNF-α has also been reported to enhance excitotoxicity through synergistic stimulation of the TNF and NMDA receptors [72].

IL-1β is known to be a driving force in the inflammatory process in AD, and it promotes the synthesis and processing of APP [73]. IL-1β affects ion currents, intracellular Ca²⁺ homeostasis, and membrane potentials and suppresses long-term potentiation, thus contributing to dysfunction and inflammation [74]. A recent report indicated that the cytoplasmic receptor NALP3 inflammasome is involved in the innate immune response in AD [75]. Activation of the microglial NALP3 inflammasome is initiated by phagocytosis of fAβ and induces lysosomal damage and cathepsin B release. Moreover, it leads to the cleavage of pro-IL-1β/pro-IL-18 into IL-1β/IL-18 by caspase-1. Subsequently, IL-1β activates the secretion of several proinflammatory and chemotactic mediators [75].

Wnt signaling plays an important role in neural development, including synaptic differentiation. Wnt5a and its receptor Frizzled-5 have been shown to be upregulated in the AD mouse brain [76], and activation of Wnt5a signaling enhances Aβ-evoked neurotoxicity by induced TNF-α and IL-1β [76]. In contrast, postsynaptic damage induced by oAβ in hippocampal neurons is reported to be prevented by Wnt5a [77]. This discrepancy can be explained by the fact that basal Wnt5a has synaptoprotective activity, but excessive Wnt5a may induce proinflammatory factors.

4. Phagocytosis of Microglia

Microglial phagocytosis of neuronal debris and Aβ plays a pivotal role in AD. Phagocytosis is associated with inflammation during uptake of microbes via TLRs and Fc receptors, while phagocytosis of apoptotic cells is executed without inflammation via phosphatidylserine receptors such as T-cell-immunoglobulin-mucin-4 (TIM-4) [78, 79]. Milk-fat-globule-EGF-factor-8 (MFG-E8), secreted by activated microglia or macrophages, also binds to phosphatidylserine exposed on plasma membranes of apoptotic cells [80, 81]. Phagocytosis with inflammation may be toxic to neurons because of the production of inflammatory molecules such as proinflammatory cytokines, NO, and ROS. However, phagocytosis of Aβ contributes to microglial neuroprotection in AD. Peptidoglycan, the TLR2 ligand, and unmethylated DNA CpG motifs, the TLR9 ligand, increase Aβ phagocytosis through protein-coupled formyl peptide receptor-like 2 [82, 83]. Similarly, LPS, the TLR4 ligand, increases phagocytosis through the CD14 receptor [84]. TLR4 mutation exacerbates the Aβ burden in mouse models of AD [85].

5. Molecules Able to Induce Microglial Neuroprotective Properties

5.1. Fractalkine. Degenerating neurons produce signaling molecules that regulate microglial phagocytosis and neuroprotection. Some of this signaling may be controlled by chemokines and chemokine receptors, which are widely
expressed throughout the central nervous system [86]. We have shown that the soluble CX3C chemokine fractalkine (FKN), secreted from damaged neurons, promotes microglial phagocytosis of neuronal debris through the release of MFG-E8 and induces the expression of the antioxidant enzyme HO-1 in microglia, resulting in neuroprotection against glutamate toxicity [87]. The end-products of HO-1 including biliverdin, carbon monoxide, and iron provide cellular and tissue protection through antiinflammatory, antiapoptotic, or antioxidative effects [88]. Numerous studies have demonstrated that upregulation of HO-1 expression in the CNS may be beneficial to counteract neuroinflammation and neurodegenerative diseases [89]. The neuroprotective effect of FKN is abolished by treatment with the HO-1 inhibitor tin-mesoporphyrin IX (SnMP). Moreover, FKN suppresses microglial NO, IL-6, and TNF-α production [90]. FKN signaling is deficient in AD brains and is downregulated by Aβ. CX3CR1, the fractalkine receptor, is a key member of the microglial pathway that protects against AD-related cognitive deficits that are associated with aberrant microglial activation and elevated inflammatory cytokines [91]. Mice lacking the CX3CR1 receptor show cognitive dysfunction as demonstrated by contextual fear conditioning and Morris water maze tests, deficits in motor learning, and a significant impairment in long-term potentiation via increase in IL-1β [92]. CX3CR1 deficiency worsens the AD-related neuronal and behavioral deficits [91]. In contrast, CX3CR1 deficiency is reported to reduce Aβ deposition in AD mouse models [93]. Thus, FKN-CX3CR1 signaling in AD is still controversial.

5.2. IL-34. The dimeric glycoprotein IL-34, which is mainly expressed in neurons, may also be a neuronal cytokine that regulates microglial function. The major function of IL-34 is to stimulate the differentiation and proliferation of monocytes and macrophages via the colony-stimulating-factor-(CSF-)1 receptor [94]. We have shown that IL-34 induces microglial proliferation and antioxidant HO-1 production and enhances the degradation of Aβ via insulin degrading enzyme (IDE) (also known as Aβ degrading enzyme) and that IL-34 reduces the amount of Aβ and ROS present in the supernatant of neuron-microglia cocultures, resulting in microglial neuroprotection against Aβ toxicity [95]. IDE activity is critical in determining the level of Aβ. The levels of hippocampal IDE protein and activity have been shown to be reduced in AD [96]. Enhanced IDE activity in IDE(APP)/PS1 double-transgenic mice decreased Aβ levels and prevented the development of AD pathology [97]. Moreover, single intracerebroventricular injection of IL-34 effectively suppressed the impairment of associative learning in an APP/PS1 transgenic mouse model of AD [95]. The injection of IL-34 may act directly on microglia, which can rapidly eliminate Aβ via upregulation of IDE and exert antioxidant effect via HO-1.

5.3. M-CSF. CSF-1, also known as macrophage colony-stimulating factor (M-CSF), is another ligand of the CSF-1 receptor. M-CSF enables the acidification of macrophage lysosomes and subsequently the degradation of internalized Aβ [98]. Intraperitoneal injection of M-CSF prevents memory disturbance in APP/PS1 mice by inducing microglial phagocytosis of Aβ [99]. A recent report showed that IL-34 and M-CSF differ in their structure and the CSF-1 receptor domains that they bind, causing different bioactivities and signal activation kinetics [100]. Both IL-34 and M-CSF are useful molecules in terms of inducing microglial neuroprotective properties.

5.4. CpG. TLR9, which is located in the intracellular endosomal-lysosomal compartment in innate immune cells, detects single-stranded DNA containing unmethylated CpG. Microglia express TLR9 at higher levels than do astrocytes and neuronal cells. Thus, CpG mainly acts on microglia in the CNS. We have also shown that microglia activated by
CpG attenuate oAβ neurotoxicity [15]. While high concentrations of CpG (10 μM) induce TNF-α, IL-12, and NO in microglia and enhance neuronal damage [101, 102], lower concentrations of CpG (1 nM–100 nM) enhance microglial phagocytosis of Aβ without inflammation. Intracerebroventricular administration of CpG ameliorates both the cognitive impairments induced by oAβ and the impairment of associative learning in a Tg2576 mouse model of AD [15].

Taken together, these molecules induce neuroprotective properties in microglia through the antioxidant effect of HO-1 and Aβ clearance. HO-1 is induced by nuclear translocation of Nrf2, which is a transcription factor and reportedly plays a pivotal role in cellular survival [103, 104]. Nrf2 gene therapy also has been shown to improve memory in the mouse model of AD [105]. Moreover, Aβ clearance including phagocytosis and degradation of Aβ by microglia can decrease Aβ plaque formation and Aβ toxicity.

6. Conclusion

While Aβ, especially oAβ, is directly toxic to neurons, it may also enhance microglial neurotoxic effects by inducing inflammatory mediators. Degenerated neurons produce molecules other than Aβ that enhance microglial neurotoxicity. However, the microglial neuroprotective effect resulting from Aβ clearance and antioxidant activity is obvious in AD (Figure 3). The conditions that determine microglial toxic or protective effects remain to be elucidated. Clarifying these issues may contribute to the understanding of AD pathophysiology. A useful therapeutic strategy for AD may be to regulate microglia toward neuroprotection, specifically, Aβ clearance without inflammation.

Acknowledgments

This work was supported in part by the Global COE program Integrated Functional Molecular Medicine for Neuronal and Neoplastic Disorders, funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO).

References

[1] L. Meda, M. A. Cassatella, G. I. Szendrei et al., “Activation of microglial cells by β-amyloid protein and interferon-γ,” Nature, vol. 374, no. 6523, pp. 647–650, 1995.
[2] H. Akiyama, S. Barger, S. Barnum et al., “Key issues in Alzheimer’s disease inflammation,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000.
[3] T. F. Pais, C. Figueiredo, R. Peixoto, M. H. Braz, and S. Chatterjee, “Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway,” Journal of Neuroinflammation, vol. 5, p. 43, 2008.
[4] P. L. McGee and E. G. Meagher, “Inflammation, autotoxicity and Alzheimer disease,” Neurobiology of Aging, vol. 22, no. 6, pp. 799–809, 2001.
[5] V. Della Bianca, S. Dusi, E. Bianchini, I. Dal Prà, and F. Rossi, “β-amyloid activates the O2- forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease,” Journal of Biological Chemistry, vol. 274, no. 22, pp. 15493–15499, 1999.
[6] H. Takeuchi, S. Jin, J. Wang et al., “Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner,” Journal of Biological Chemistry, vol. 281, no. 30, pp. 21362–21368, 2006.
[7] H. Takeuchi, T. Mizuno, G. Zhang et al., “Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport,” Journal of Biological Chemistry, vol. 280, no. 11, pp. 10444–10454, 2005.
[8] S. W. Barger and A. S. Basile, “Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function,” Journal of Neurochemistry, vol. 76, no. 3, pp. 846–854, 2001.
[9] D. Piani, M. Springer, K. Frei, A. Schaffner, and A. Fontana, “Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines,” European Journal of Immunology, vol. 22, no. 9, pp. 2429–2436, 1992.
[10] K. Bordji, J. Becerril-Ortega, O. Nicole, and A. Buisson, “Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production,” Journal of Neuroscience, vol. 30, no. 47, pp. 15927–15942, 2010.
[11] D. M. Walsh, I. Klyubin, J. V. Fadeeva et al., “ Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo,” Nature, vol. 416, no. 6880, pp. 535–539, 2002.
[12] S. Li, S. Hong, N. E. Shepardson, D. M. Walsh, G. M. Shankar, and D. Selkoe, “Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake,” Neuron, vol. 62, no. 6, pp. 788–801, 2009.
[13] P. Yan, X. Hu, H. Song et al., “Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ,” Journal of Biological Chemistry, vol. 281, no. 134, pp. 24566–24574, 2006.
[14] K. L. Richard, M. Filali, P. Préfontaine, and S. Rivest, “Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid β1-42 and delay the cognitive decline in a mouse model of Alzheimer’s disease,” Journal of Neuroscience, vol. 28, no. 22, pp. 5784–5793, 2008.
[15] Y. Doi, T. Mizuno, Y. Maki et al., “Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in vitro and in vivo models of Alzheimer’s disease,” American Journal of Pathology, vol. 175, no. 5, pp. 2121–2132, 2009.
[16] G. M. Shankar, S. Li, T. H. Mehta et al., “Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory,” Nature Medicine, vol. 14, no. 8, pp. 837–842, 2008.
[17] S. Lesně, T. K. Ming, L. Kotilinek et al., “A specific amyloid-β protein assembly in the brain impairs memory,” Nature, vol. 440, no. 7082, pp. 352–357, 2006.
[18] R. Kayed, A. Pensalfini, L. Margol et al., “Annular protofibrils area structurally and functionally distinct type of amyloid oligomer,” Journal of Biological Chemistry, vol. 284, no. 7, pp. 4230–4237, 2009.

[19] C. K. Combs, J. Colleen Karlo, S. C. Kao, and G. E. Landreth, “β-amyloid stimulation of microglia anti monocytes results in TNF α-dependent expression of inducible nitric oxide synthase and neuronal apoptosis,” Journal of Neuroscience, vol. 21, no. 4, pp. 1179–1188, 2001.

[20] M. Jana, C. A. Palencia, and K. Pahan, “Fibrillar amyloid-β peptides activate microglia via TLR2: Implications for Alzheimer’s disease,” Journal of Immunology, vol. 181, no. 10, pp. 7254–7262, 2008.

[21] E. G. Reed-Geaghan, J. C. Savage, A. G. Hise, and G. E. Landreth, "CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation," Journal of Neuroscience, vol. 29, no. 38, pp. 11982–11992, 2009.

[22] C. R. Stewart, L. M. Stuart, K. Wilkinson et al., “CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer,” Nature Immunology, vol. 11, no. 2, pp. 155–161, 2010.

[23] C. M. Sondag, G. Dhawan, and C. K. Combs, “β amyloid oligomers and fibrils stimulate differential activation of primary microglia,” Journal of Neuroinflammation, vol. 6, no. 1, pp. 3693–3706, 2009.

[24] I. Maezawa, P. I. Zimin, H. Wulff, and L. W. Jin, “Amyloid-β protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity,” Journal of Biological Chemistry, vol. 286, no. 5, pp. 3693–3706, 2011.

[25] F. G. de Felice, P. T. Velasco, M. P. Lambert et al., “Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine,” Journal of Biological Chemistry, vol. 282, no. 15, pp. 11590–11601, 2007.

[26] T. Schilling and C. Eder, “Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia,” Journal of Cellular Physiology, vol. 226, no. 12, pp. 3295–3302, 2011.

[27] K. Biber, H. Neumann, K. Inoue, and H. W. G. M. Boddeke, “Neuronal ‘On’ and ‘Off’ signals control microglia,” Trends in Neurosciences, vol. 30, no. 11, pp. 596–602, 2007.

[28] D. Davalos, J. Grutzendler, G. Yang et al., “ATP mediates rapid microglial response to local brain injury in vivo,” Nature Neuroscience, vol. 8, no. 6, pp. 752–758, 2005.

[29] S. Koizumi, Y. Shigemoto-Mogami, K. Nasu-Tada et al., “UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis,” Nature, vol. 446, no. 7139, pp. 1091–1095, 2007.

[30] E. K. de Jong, I. M. Dijkstra, M. Hensens et al., “Vesicle-mediated transport and release of CCL21 in endangered neurons: a possible explanation for microglia activation remote from a primary lesion,” Journal of Neuroscience, vol. 25, no. 33, pp. 7548–7557, 2005.

[31] K. Förber and H. Kettenmann, “Physiology of microglial cells,” Brain Research Reviews, vol. 48, no. 2, pp. 133–143, 2005.

[32] M. Noda, H. Nakashii, J. Nabekura, and N. Akaie, “AMPKainate subtypes of glutamate receptor in rat cerebral microglia,” Journal of Neuroscience, vol. 20, no. 1, pp. 251–258, 2000.

[33] D. L. Taylor, L. T. Diemel, M. L. Cuzner, and J. M. Pocock, “Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer’s disease,” Journal of Neurochemistry, vol. 82, no. 5, pp. 1179–1191, 2002.

[34] T. M. Piers, S. J. Heales, and J. M. Pocock, “Positive allosteric modulation of metabotropic glutamate receptor 5 down-regulates fibrinogen-activated microglia providing neuronal protection,” Neuroscience Letters, vol. 505, no. 2, pp. 140–145, 2011.

[35] L. Lyras, N. J. Cairns, A. Jenner, P. Jenner, and B. Halliwell, “An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2061–2069, 1997.

[36] S. Shimohama, H. Tanino, N. Kawakami et al., “Activation of NADPH oxidase in Alzheimer’s disease’s brain,” Biochemical and Biophysical Research Communications, vol. 273, no. 1, pp. 5–9, 2000.

[37] J. El Khoury, S. E. Hickman, C. A. Thomas, L. Cao, S. C. Silverstein, and I. D. Loike, “Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils,” Nature, vol. 382, no. 6593, pp. 716–719, 1996.

[38] D. R. McDonald, K. R. Brunden, and G. E. Landreth, “Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia,” Journal of Neuroscience, vol. 17, no. 7, pp. 2284–2294, 1997.

[39] M. L. Block, “NADPH oxidase as a therapeutic target in Alzheimer’s disease,” BMC Neuroscience, vol. 9, supplement 2, article S8, 2008.

[40] M. Manczak, T. S. Anekonda, E. Henson, B. S. Park, J. Quinn, and P. H. Reddy, “Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression,” Human Molecular Genetics, vol. 15, no. 9, pp. 1437–1449, 2006.

[41] P. H. Reddy and M. F. Beal, “Amyloid β, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease,” Trends in Molecular Medicine, vol. 14, no. 2, pp. 45–53, 2008.

[42] T. Alkam, A. Nitta, H. Mizoguchi, A. Itoh, and T. Nabeshima, “A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Aβ25-35,” Behavioural Brain Research, vol. 180, no. 2, pp. 139–145, 2007.

[43] R. H. Milton, R. Abeti, S. Averaimo et al., “CLIC1 function is required for β-amyloid-induced generation of reactive oxygen species by microglia,” Journal of Neuroscience, vol. 28, no. 45, pp. 11488–11499, 2008.

[44] M. D. Mains, “The heme oxygenase system: a regulator of heme oxygenase activity and receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines,” European Journal of Pharmacology, vol. 376, pp. 517–554, 1997.

[45] H. Atamna and W. H. Frey II, “A role for heme in Alzheimer’s disease: heme binds amyloid β and has altered metabolism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 11153–11158, 2004.

[46] M. Takahashi, S. Doré, C. D. Ferris et al., “Amyloid precursor protein inhibits heme oxygenase activity and augments neurotoxicity in Alzheimer’s disease,” Neuron, vol. 28, no. 2, pp. 461–473, 2000.

[47] D. Piani, M. Spranger, K. Frei, A. Schaffner, and A. Fontana, “Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines,” European Journal of Immunology, vol. 22, no. 9, pp. 2429–2436, 1992.
Journal of Neuroimmunology, vol. 205, no. 1-2, pp. 92-94, 2005.

M. R. Zhou, G. Chen, X. Wen, X. Wang, S. Zhang et al., "Triptolide inhibits amyloid-β-induced microglial activation," Neurobiology of Aging, vol. 27, no. 5, pp. 991-998, 2006.

K. Bordji, J. Becerril-Ortega, O. Nicole, and A. Buisson, "Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production," Journal of Neuroscience, vol. 30, no. 47, pp. 15927-15942, 2010.

N. Hori and D. O. Carpenter, "Functional and morphological changes induced by transient in vivo ischemia," Experimental Neurology, vol. 129, no. 2, pp. 279-289, 1994.

J. W. Swann, S. Al-Noori, M. Jiang, and C. L. Lee, "Spine loss and other dendritical abnormalities in epilepsy," Hippocampus, vol. 10, no. 3, pp. 617-625, 2000.

S. Goel, S. B. Wharton, L. P. Brett, and I. R. Whittle, "Morphological changes and stress responses in neurons in cerebral cortex infiltrated by diffuse astrocytoma," Neuropathology, vol. 23, no. 4, pp. 262-270, 2003.

T. C. Dickson, C. E. King, G. H. McCormack, and J. C. Vickers, "Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer’s disease," Experimental Neurology, vol. 156, no. 1, pp. 100-110, 1999.

J. Liang, H. Takeuchi, Y. Doi et al., "Excitatory amino acid transporter expression by astrocytes is neuroprotective against microglial excitotoxicity," Brain Research, vol. 1210, pp. 11-19, 2008.

I. Yawata, H. Takeuchi, Y. Doi, J. Liang, T. Mizuno, and A. Suzumura, "Macrophage-induced neurotoxicity is mediated by glutamate and attenuated by glutaminase inhibitors and gap junction inhibitors," Life Sciences, vol. 82, no. 21-22, pp. 1111-1116, 2008.

H. Takeuchi, S. Jin, H. Suzuki et al., "Blockade of microglial glutamate release protects against ischemic brain injury," Experimental Neurology, vol. 214, no. 1, pp. 144-146, 2008.

J. Shi, H. Takeuchi, I. Yawata et al., "Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice," Tohoku Journal of Experimental Medicine, vol. 217, no. 2, pp. 87-92, 2009.

H. Takeuchi, H. Mizoguchi, Y. Doy et al., "Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer’s disease," PLoS One, vol. 6, no. 6, Article ID e21108, 2011.

J. Brito-Moreira, A. C. Paula-Lima, T. R. Bomfim et al., "Amyloid-β oligomers induce glutamate release from hippocampal neurons," Current Alzheimer Research, vol. 8, no. 5, pp. 552-562, 2011.

J. Jiao, B. Xue, L. Zhang et al., "Triptolide inhibits amyloid-β1-42-induced TNF-α and IL-1β production in cultured rat microglia," Journal of Neuroimmunology, vol. 205, no. 1-2, pp. 32-36, 2008.

G. Sebastiani, C. Morissette, C. Lagacé et al., "The cAMP-specific phosphodiesterase 4B mediates Aβ-induced microglial activation," Neurobiology of Aging, vol. 27, no. 3, pp. 691-701, 2006.

R. Kuno, J. Wang, J. Kawanokuchi, H. Takeuchi, T. Mizuno, and A. Suzumura, "Autocrine activation of microglia by tumor necrosis factor-α," Journal of Neuroimmunology, vol. 162, no. 1-2, pp. 89-96, 2005.

M. Kaul, G. A. Garden, and S. A. Lipton, "Pathways to neuronal injury and apoptosis in HIV-associated dementia," Nature, vol. 410, no. 6831, pp. 988-994, 2001.

D. L. Taylor, F. Jones, E. S. F. Chen Seho Kubota, and J. M. Pocock, "Stimulation of microglial metabotropic glutamate receptor mGlur2 triggers tumor necrosis factor α-induced neurotoxicity in concert with microglial-derived Fas ligand," Journal of Neuroscience, vol. 25, no. 11, pp. 2952-2964, 2005.

E. A. Eugenín, D. Eckardt, M. Theis, K. Willecke, M. V. L. Bennett, and J. C. Sáez, "Microglia at brain stab wounds express connexin 43 and in vitro form functional gap junctions after treatment with interferon-γ and tumor necrosis factor-α," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 4190-4195, 2001.

Z. Yu, G. Cheng, X. Wen, G. D. Wu, W. T. Lee, and D. Pleasure, "Tumor necrosis factor α increases neuronal vulnerability to excitotoxic necrosis by inducing expression of the AMPA-glutamate receptor subunit GluR1 via an acid sphingomyelinase-and NF-xB-dependent mechanism," Neurobiology of Disease, vol. 11, no. 1, pp. 199-213, 2002.

I. Bernardino, S. Xapelli, A. P. Silva et al., "Modulator effects of interleukin-1β and tumor necrosis factor-α on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures," Journal of Neuroscience, vol. 25, no. 29, pp. 6734-6744, 2005.

A. M. Floden, S. Li, and C. K. Combs, "β-Amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor α and NMDA receptors," Journal of Neuroscience, vol. 25, no. 10, pp. 2566-2575, 2005.

A. H. Moore and M. K. O’Banion, "Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease," Advanced Drug Delivery Reviews, vol. 54, no. 12, pp. 1627-1656, 2002.

M. A. Lynch, "Age-related impairment in long-term potentiation in hippocampus: A role for the cytokine, interleukin-1β?" Progress in Neurobiology, vol. 56, no. 5, pp. 571-589, 1998.

A. Halle, V. Hornung, G. C. Petzold et al., "The NALP3 inflammasome is involved in the innate immune response to amyloid-β," Nature Immunology, vol. 9, no. 8, pp. 857-863, 2008.

E. Torres, M. D. Gutierrez-Lopez, A. Mayado, A. Rubio, E. O’Shea, and M. I. Colado, "Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxyamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity," Journal of Neuroinflammation, vol. 8, p. 53, 2011.
[77] W. Cerpa, G. G. Farías, I. A. Godoy, M. Fuenzalida, C. Bonansco, and N. C. Inestrosa, “Wnt-5a occludes Aβ oligomer-induced depression of glutamatergic transmission in hippocampal neurons,” Molecular Neurodegeneration, vol. 5, no. 1, p. 1, 2010.

[78] H. Neumann, M. R. Kotter, and R. J. M. Franklin, “Debris clearance by microglia: an essential link between degeneration and regeneration,” Brain, vol. 132, no. 2, pp. 288–295, 2009.

[79] M. Miyanishi, K. Tada, M. Koike, Y. Uchiyama, T. Kitamura, and S. Nagata, “Identification of Tim4 as a phosphatidylserine receptor,” Nature, vol. 450, no. 7168, pp. 435–439, 2007.

[80] R. Hanayama, M. Tanaka, K. Miwa, A. Shinohara, A. Iwamoto, and S. Nagata, “Identification of a factor that links apoptotic cells to phagocytes,” Nature, vol. 417, no. 6885, pp. 182–187, 2002.

[81] P. Iribarren, K. Chen, J. Hu et al., “CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid β 1–42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2,” The FASEB Journal, vol. 19, no. 14, pp. 2032–2034, 2005.

[82] K. Chen, P. Iribarren, J. Hu et al., “Activation of toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid β peptide,” Journal of Biological Chemistry, vol. 281, no. 6, pp. 3631–3639, 2006.

[83] Y. Liu, S. Walter, M. Stagi et al., “LPS receptor (CD14): a receptor for phagocytosis of Alzheimer’s amyloid peptide,” Brain, vol. 128, no. 8, pp. 1778–1789, 2005.

[84] K. Tahara, H. D. Kim, J. J. Jin, J. A. Maxwell, L. Li, and K. I. Fukuchi, “Role of toll-like receptor signalling in Aβ uptake and clearance,” Brain, vol. 129, pp. 3006–3019, 2006.

[85] P. B. Tran and R. J. Miller, “Chimokine receptors: signposts to brain development and disease,” Nature Reviews Neuroscience, vol. 4, no. 6, pp. 444–455, 2003.

[86] M. Noda, Y. Doi, J. Liang et al., “Fractalkine attenuates excitotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression,” Journal of Biological Chemistry, vol. 286, no. 3, pp. 2308–2319, 2011.

[87] D. Morse, L. Lin, A. M. K. Choi, and S. W. Ryter, “Heme oxygenase-1, a critical arbitrator of cell death pathways in lung injury and disease,” Free Radical Biology and Medicine, vol. 47, no. 1, pp. 1–12, 2009.

[88] P. J. Syapin, “Regulation of haeme oxygenase-1 for treatment of neuroinflammation and brain disorders,” British Journal of Pharmacology, vol. 155, no. 5, pp. 623–640, 2008.

[89] T. Mizuno, J. Kawanokuchi, K. Numata, and A. Suzumura, “Production and neuroprotective functions of fractalkine in the central nervous system,” Brain Research, vol. 979, no. 1-2, pp. 65–70, 2003.

[90] S. H. Cho, B. Sun, Y. Zhou et al., “CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease,” Journal of Biological Chemistry, vol. 286, no. 37, pp. 32713–32722, 2011.

[91] J. T. Rogers, J. M. Morganti, A. D. Bachstetter et al., “CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity,” Journal of Neuroscience, vol. 31, no. 45, pp. 16241–16250, 2011.